Understanding How Variants in LOXL1 Affect Pseudoexfoliation Glaucoma Risk

About the Research Project
Program
Award Type
Postdoctoral Fellowship
Award Amount
$150,000
Active Dates
July 01, 2024 - June 30, 2026
Grant ID
G2024001F
Acknowledgement
Goals
The purpose of this project is to determine how variants in the LOXL1 encoding gene alter the protein’s structure and function, thereby altering risk for pseudoexfoliation glaucoma.
Summary
Genetic variants in LOXL1 can alter risk for pseudoexfoliation glaucoma (XFG), a blinding disease that affects more than 10 million people. This project seeks to determine how these variants alter the structure and function of the LOXL1 protein. Successful completion of this project will provide a better understanding of how LOXL1 variants contribute to XFG and provide groundwork for therapeutic development.
Unique and Innovative
This project would be the first to characterize the protein structure of LOXL1 with and without pseudoexfoliation glaucoma-associated variants. Results will offer novel insight into how pseudoexfoliation glaucoma-associated variants contribute to the disease by altering interactions with fibulin-5, a protein necessary for proper LOXL1 localization.
Foreseeable Benefits
The successful completion of this project will result in a better understanding of the molecular mechanisms by which pseudoexfoliation glaucoma-associated variants affect disease risk. This improved knowledge will allow for the development of new therapies that can target these specific mechanisms.
Related Grants
National Glaucoma Research
Mitochondria in Retinal Ganglion Cells
Active Dates
July 01, 2025 - June 30, 2027

Principal Investigator
Rob Nickells, PhD
Current Organization
University of Wisconsin-Madison
National Glaucoma Research
Role of a Key Gene, Angptl7, in Steroid-Induced Glaucoma
Active Dates
July 01, 2025 - June 30, 2027

Principal Investigator
W. Daniel Stamer, PhD
Current Organization
Duke University
National Glaucoma Research
Assessment of Vascular Resistance in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027

Principal Investigator
Brad Fortune, OD, PhD
Current Organization
Legacy Devers Eye Institute